Biogen

BIIB

Market cap $28.9B

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?

Biogen climbs 11.5% YTD as new drugs, pipeline progress and M&A activity fuel confidence in Biogen???s multiyear turnaround.

NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Biogen Inc.: Due to the forgoing, The Gross Law Firm is investigating potential securities fraud claims on behalf of certain Biogen Inc. investors. If you incurred a loss on your BIIB investment, please contact us using the link below to discuss your rights.

NEW YORK, May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Italy's antitrust authority said ​on Wednesday it ‌had opened an investigation into drug maker ​Biogen Italia ​and its parent Biogen ⁠over alleged abuse ​of dominant position.

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. (“Biogen” or the “Company”) (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Biogen stock is struggling to break above its $206 resistance level, which also represents the +1σ band formed from the VWAP.

Biogen shares dropped approximately 6.4% in a single session after Phase 2 CELIA trial data for diranersen missed its primary endpoint -- wiping out billions in market value. NEW YORK, May 22, 2026 /PRNewswire/ -- Biogen Inc. (NASDAQ: BIIB) investors lost approximately 6.4% per share on May 14, 2026, when the company disclosed that its Phase 2 "CELIA" trial for diranersen (BIIB080) failed to meet its primary dose-response endpoint in early Alzheimer's disease.

U.S. Food & Drug Administration (FDA) events crystallize the risk/reward thesis for many biotechnology stocks, and Biogen Inc.'s NASDAQ: BIIB latest Alzheimer's update shows why that trade can turn quickly.

NEW YORK, May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Biogen Inc. ("Biogen" or the "Company") (NASDAQ: BIIB). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.